Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Gross Profit for the year ending December 31, 2023: USD 1.35 M

Lumosa Therapeutics Co., Ltd. Gross Profit is USD 1.35 M for the year ending December 31, 2023, a 184.47% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Lumosa Therapeutics Co., Ltd. Gross Profit for the year ending December 31, 2022 was USD 474.99 K, a 33.15% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit for the year ending December 31, 2021 was USD 356.74 K, a -23.73% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit for the year ending December 31, 2020 was USD 467.76 K, a -86.65% change year over year.
  • Lumosa Therapeutics Co., Ltd. Gross Profit for the year ending December 31, 2019 was USD 3.50 M.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email